Davide Roccarina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Davide Roccarina has a total of 317 co-authors. Here are the top co-authors by number of shared publications:
- Antonio Gasbarrini
Department of Internal Medicine and Gastroenterology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy
10 shared publications - Francesco Franceschi
Department of Emergency Medicine, Policlinico Gemelli/IRCCS, University of Catholic of Sacred Heart, 00168 Rome, Italy
6 shared publications Giovanni Gasbarrini
6 shared publications- Francesco Vizzutti
Department of Experimental and Clinical Medicine University of Florence Florence Italy
5 shared publications Bianca Giupponi
4 shared publications- Dario Saltini
Severe Liver Diseases Departmental Unit (M.E.C.), AOU Policlinico of Modena, University of Modena and Reggio Emilia, Modena, Italy
4 shared publications
Latest Publications
- Open Access
- 14 October 2026
- Published by Elsevier in JHEP Reports
Spleen stiffness to rule out high-risk varices in advanced chronic liver disease: an individual patient data meta-analysis
- 14 October 2026
- Published by Elsevier in JHEP Reports
Open AccessSpleen stiffness to rule out high-risk varices in advanced chronic liver disease: an individual patient data meta-analysis
- Open Access
- 18 September 2026
- Published by Wiley in Journal of Ultrasound in Medicine
Diagnostic Accuracy of Quantitative Ultrasound Liver Fat Estimation with MRI ‐ PDFF as the Reference Standard
Objectives: To assess the performance of 3 ultrasound‐based liver fat quantification algorithms—tissue attenuation imaging (TAI), tissue scatter imaging (TSI; Nakagami parameter), and ultrasound‐derived fat fraction (USFF)—using magnetic resonance imaging‐derived proton density fat fraction (MRI‐PDFF) as the reference standard. Methods: In this prospective, IRB‐approved, HIPAA‐compliant study conducted at 2 North American centers, adults with or at risk for hepatic steatosis underwent quantitative ultrasound and same‐day MRI‐PDFF. The US examinations were performed with the Samsung RS85 system (Samsung Medison, Seoul, South Korea) using a C1‐5S transducer. The software version utilized was 2.08.01.3538. Correlations were assessed using Spearman's rho. Diagnostic performance for steatosis grades S > 0, S > 1, and S > 2 was evaluated using AUROC analysis. Overall accuracy across grades was also assessed with the Obuchowski measure. Correlations and AUROCs were compared using Steiger's and DeLong's tests, respectively. Results: Among 181 participants (113 women; median age, 57 years), MRI‐PDFF correlated strongly with TAI and USFF (rho, 0.77 and 0.79) and moderately with TSI (rho, 0.57). For S > 0, AUROCs were 0.92 for TAI, 0.78 for TSI, and 0.93 for USFF; for S > 1, 0.88, 0.77, and 0.89; and for S > 2, 0.81, 0.73, and 0.83, respectively. Obuchowski measures were 0.87, 0.76, and 0.88. TAI and USFF were significantly more accurate than TSI ( p = .03 and p = .02), with no significant difference between them ( p = .79). Conclusions: TAI and USFF showed high, comparable performance for detecting hepatic steatosis and outperformed TSI. USFF was numerically superior to TAI, without significant incremental benefit. Discrimination between moderate and severe steatosis remained limited in the US evaluation.
- 18 September 2026
- Published by Wiley in Journal of Ultrasound in Medicine
Open AccessDiagnostic Accuracy of Quantitative Ultrasound Liver Fat Estimation with MRI ‐ PDFF as the Reference Standard
Objectives: To assess the performance of 3 ultrasound‐based liver fat quantification algorithms—tissue attenuation imaging (TAI), tissue scatter imaging (TSI; Nakagami parameter), and ultrasound‐derived fat fraction (USFF)—using magnetic resonance imaging‐derived proton density fat fraction (MRI‐PDFF) as the reference standard. Methods: In this prospective, IRB‐approved, HIPAA‐compliant study conducted at 2 North American centers, adults with or at risk for hepatic steatosis underwent quantitative ultrasound and same‐day MRI‐PDFF. The US examinations were performed with the Samsung RS85 system (Samsung Medison, Seoul, South Korea) using a C1‐5S transducer. The software version utilized was 2.08.01.3538. Correlations were assessed using Spearman's rho. Diagnostic performance for steatosis grades S > 0, S > 1, and S > 2 was evaluated using AUROC analysis. Overall accuracy across grades was also assessed with the Obuchowski measure. Correlations and AUROCs were compared using Steiger's and DeLong's tests, respectively. Results: Among 181 participants (113 women; median age, 57 years), MRI‐PDFF correlated strongly with TAI and USFF (rho, 0.77 and 0.79) and moderately with TSI (rho, 0.57). For S > 0, AUROCs were 0.92 for TAI, 0.78 for TSI, and 0.93 for USFF; for S > 1, 0.88, 0.77, and 0.89; and for S > 2, 0.81, 0.73, and 0.83, respectively. Obuchowski measures were 0.87, 0.76, and 0.88. TAI and USFF were significantly more accurate than TSI ( p = .03 and p = .02), with no significant difference between them ( p = .79). Conclusions: TAI and USFF showed high, comparable performance for detecting hepatic steatosis and outperformed TSI. USFF was numerically superior to TAI, without significant incremental benefit. Discrimination between moderate and severe steatosis remained limited in the US evaluation.
- 1 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70725
Response to: Passive Stent Expansion as a Confounder in Under‐Dilated TIPS Outcomes
- 1 June 2026
- Published by Wiley in Liver International
- Vol. 46 (7) , e70725
Response to: Passive Stent Expansion as a Confounder in Under‐Dilated TIPS Outcomes
- Open Access
- 15 May 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (7) , 859-861
Rethinking TIPS: From clinical insight to device innovation
- 15 May 2026
- Published by Elsevier in Digestive and Liver Disease
- Vol. 58 (7) , 859-861
Open AccessRethinking TIPS: From clinical insight to device innovation
- 16 January 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 1037-1039
Editorial: TIPS in the Era of Aging and Metabolic Comorbidity: Rethinking Risks and Rewards
- 16 January 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
- Vol. 63 (7) , 1037-1039
Editorial: TIPS in the Era of Aging and Metabolic Comorbidity: Rethinking Risks and Rewards
- Open Access
- 9 December 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (7) , 3534-3542
Contrast enhanced ultrasound evaluation of nephron sparing treatment for renal cell carcinoma
Purpose: To determine the accuracy of CEUS in identifying residual or recurrent tumor post nephron-sparing procedures. Materials and methods: CEUS studies performed post nephron sparing procedure (RFA, cryoablation, MWA, partial nephrectomy) from January 2018 to May 2025 were retrospectively reviewed at 2 centers. Informed consent was waived. Patient charts were reviewed for follow-up procedures and patient status. CEUS studies were performed on a Philips Epic ultrasound with a C5-1 transducer using Lumason with a dose of 1.0 to 2.0 cc. A 3-minute cine clip was saved. An examination was considered a true positive if there was contrast in the procedure site and either biopsy proven tumor or persistent enhancement for over 1 year. An examination was considered a true negative if there was no contrast enhancement in the procedure site. Results: There were 193 lesions in 188 patients. (mean age 68.0 years +/− 1.4 {SD} (range 33–90) ; 115 men). There were 16 radiofrequency ablation, 38 cryoablations, 4 microwave ablations, and 135 partial nephrectomies. The average lesion size was 2.9 cm (IQR 2.2,3.7; range 1.4–7.1 cm). There were 17 (8.8%) true positive cases and 176 (91.2%) true negative cases. Time of follow-up ranged from 1 to 336 months (mean 35.1, IQR 12, 70). There were no false positive or false negative cases based on biopsy and long-term follow-up. There were 92 (47.7%) that also had CECT. There was 96.7% concordance of CEUS with CT. There were 3 CEUS cases positive with a negative CECT. Conclusions: CEUS is an accurate method in determining residual or recurrent tumor in patients having nephron sparing procedures.
- 9 December 2025
- Published by Springer Nature in Abdominal Radiology
- Vol. 51 (7) , 3534-3542
Open AccessContrast enhanced ultrasound evaluation of nephron sparing treatment for renal cell carcinoma
Purpose: To determine the accuracy of CEUS in identifying residual or recurrent tumor post nephron-sparing procedures. Materials and methods: CEUS studies performed post nephron sparing procedure (RFA, cryoablation, MWA, partial nephrectomy) from January 2018 to May 2025 were retrospectively reviewed at 2 centers. Informed consent was waived. Patient charts were reviewed for follow-up procedures and patient status. CEUS studies were performed on a Philips Epic ultrasound with a C5-1 transducer using Lumason with a dose of 1.0 to 2.0 cc. A 3-minute cine clip was saved. An examination was considered a true positive if there was contrast in the procedure site and either biopsy proven tumor or persistent enhancement for over 1 year. An examination was considered a true negative if there was no contrast enhancement in the procedure site. Results: There were 193 lesions in 188 patients. (mean age 68.0 years +/− 1.4 {SD} (range 33–90) ; 115 men). There were 16 radiofrequency ablation, 38 cryoablations, 4 microwave ablations, and 135 partial nephrectomies. The average lesion size was 2.9 cm (IQR 2.2,3.7; range 1.4–7.1 cm). There were 17 (8.8%) true positive cases and 176 (91.2%) true negative cases. Time of follow-up ranged from 1 to 336 months (mean 35.1, IQR 12, 70). There were no false positive or false negative cases based on biopsy and long-term follow-up. There were 92 (47.7%) that also had CECT. There was 96.7% concordance of CEUS with CT. There were 3 CEUS cases positive with a negative CECT. Conclusions: CEUS is an accurate method in determining residual or recurrent tumor in patients having nephron sparing procedures.
- Open Access
- 13 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Shunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS
- 13 November 2025
- Published by Elsevier in JHEP Reports
- Vol. 8 (1)
Open AccessShunt magnitude is a key determinant of overt hepatic encephalopathy in patients undergoing TIPS
- 3 January 2025
- Published by Wolters Kluwer Health in Hepatology
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective TIPS in patients with cirrhosis
Background & Aims: In clinical practice, the reduction of porto-caval pressure gradient (PCPG) following trans-jugular intra-hepatic porto-systemic shunt (TIPS) does not always meet the recommendation of current guidance. We evaluated the impact of different degrees of PCPG reduction, measured at the end of an elective TIPS, on ascites control, recurrence of portal hypertension-related bleeding (PHRB) and survival. Approach and Results: Cirrhotic patients receiving TIPS for refractory ascites (RA) or for the secondary prophylaxis of PHRB were consecutively enrolled. Reduction in PCPG was defined inadequate (IHR) in patients not achieving a PCPG Export
- 3 January 2025
- Published by Wolters Kluwer Health in Hepatology
End-procedural adherence to recommended hemodynamic targets does not improve the outcome of elective TIPS in patients with cirrhosis
Background & Aims: In clinical practice, the reduction of porto-caval pressure gradient (PCPG) following trans-jugular intra-hepatic porto-systemic shunt (TIPS) does not always meet the recommendation of current guidance. We evaluated the impact of different degrees of PCPG reduction, measured at the end of an elective TIPS, on ascites control, recurrence of portal hypertension-related bleeding (PHRB) and survival. Approach and Results: Cirrhotic patients receiving TIPS for refractory ascites (RA) or for the secondary prophylaxis of PHRB were consecutively enrolled. Reduction in PCPG was defined inadequate (IHR) in patients not achieving a PCPG Export
- 17 October 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (4) , 1763-1774
Diagnostic insights into splenic pathologies: the role of multiparametric ultrasound
Ultrasound (US) evaluation of the spleen is mandatory in the assessment of patients with chronic liver disease, and splenomegaly can be a sign of systemic diseases. However, due to the lack of distinctive ultrasound findings in specific splenic pathologies, clinical diagnosis can be very challenging. Splenomegaly, defined by increased splenic dimensions, can indicate underlying systemic conditions and is a common manifestation of portal hypertension (PH). Ultrasound and Doppler techniques help assessing splenic involvement in PH. Splenic stiffness measurement, using elastography, offers additional diagnostic accuracy, especially when liver stiffness measurements are inconclusive. CEUS enhances the diagnostic capability for focal splenic lesions, differentiating between benign and malignant lesions by their distinct enhancement patterns, and plays also a critical role in the context of splenic traumatic pathology. Overall, CEUS significantly improves the characterization of splenic pathology, reducing the need for invasive procedures and ensuring appropriate patient management. This review article describes the normal US findings of the spleen and examines the role of multiparametric US in the evaluation of the most common splenic pathologies encountered in the daily clinical practice.
- 17 October 2024
- Published by Springer Nature in Abdominal Radiology
- Vol. 50 (4) , 1763-1774
Diagnostic insights into splenic pathologies: the role of multiparametric ultrasound
Ultrasound (US) evaluation of the spleen is mandatory in the assessment of patients with chronic liver disease, and splenomegaly can be a sign of systemic diseases. However, due to the lack of distinctive ultrasound findings in specific splenic pathologies, clinical diagnosis can be very challenging. Splenomegaly, defined by increased splenic dimensions, can indicate underlying systemic conditions and is a common manifestation of portal hypertension (PH). Ultrasound and Doppler techniques help assessing splenic involvement in PH. Splenic stiffness measurement, using elastography, offers additional diagnostic accuracy, especially when liver stiffness measurements are inconclusive. CEUS enhances the diagnostic capability for focal splenic lesions, differentiating between benign and malignant lesions by their distinct enhancement patterns, and plays also a critical role in the context of splenic traumatic pathology. Overall, CEUS significantly improves the characterization of splenic pathology, reducing the need for invasive procedures and ensuring appropriate patient management. This review article describes the normal US findings of the spleen and examines the role of multiparametric US in the evaluation of the most common splenic pathologies encountered in the daily clinical practice.
- 1 October 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (1) , e240162
Intersystem and Interoperator Agreement of US Attenuation Coefficient for Quantifying Liver Steatosis
Substantial variability in US attenuation coefficient values across systems precludes their interchangeability for diagnosing and monitoring liver steatosis.
- 1 October 2024
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 313 (1) , e240162
Intersystem and Interoperator Agreement of US Attenuation Coefficient for Quantifying Liver Steatosis
Substantial variability in US attenuation coefficient values across systems precludes their interchangeability for diagnosing and monitoring liver steatosis.